Contact:

David K. Waldman/John W. Heilshorn	The Quigley Corporation
Lippert Heilshorn & Associates	Carl Fonash
(212) 838-3777	Shareholder Relations
dwaldman@lhai.com	(267) 880-1111

The Quigley Corporation Engages Amper, Politziner & Mattia, P.C. as Independent Accountants

DOYLESTOWN, PA. - July 16, 2004 - The Quigley Corporation (Nasdaq: QGLY) today announced that it has dismissed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm. The Company has engaged Amper, Politziner & Mattia, P.C. (APM) as independent accountants. The dismissal of PwC and engagement of APM was approved by the Audit Committee of the Company.

Guy J. Quigley, Chairman, President and Chief Executive Officer stated, "We look forward to working with Amper, Politziner & Mattia, P.C. as our independent accountants. APM brings more than 35 years of experience and is one of the larger independent CPA firms in the United States. Importantly, APM possesses an outstanding reputation and offers services at competitive rates."

The reports of PwC on the Company's financial statements for the past two fiscal years did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principle, except for the 2003 fiscal year opinion, which contained a reference for a restatement of the 2002 consolidated financial statements to revise the accounting for certain warrants. During the two most recent fiscal years and through July 8, 2004, there were no disagreements with PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PwC, would have caused them to make reference to the subject matter of any such disagreement in connection with its reports on the financial statements for such years. During the two most recent fiscal years and through July 8, 2004, there were no reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).

About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE® family of patented zinc gluconate glycine (ZIGG™) lozenges and sugar free tablets. COLD-EEZE is the only (ZIGG) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com ), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned products to be studied or marketed.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.